10/06/2026
By 2030, nearly 1 million Canadians could be living with dementia. Supporting an aging, at-risk population means planning now, with diagnostic technology that makes dementia care arrive earlier, faster, and more personalized.
Blood-based biomarker (BBM) testing could be that solution. BBMs are quickly being adopted into clinical practice worldwide.
That's why OBI is partnering with Alzheimer Society of Ontario and the Weston Brain Institute on the Canada Blood-based Biomarkers Readiness & Pathway Development initiative. Guided by experts, patient partners, and advocates, the project will inform a coordinated, evidence-based approach to BBM use across Canada's dementia care system.
A $200K investment from the Weston Family Foundation helps make this work possible. We're honoured to partner with two leaders in brain health to accelerate responsive, innovative dementia care.
🔗 Learn more: https://westonfoundation.ca/weston-brain-institute/